CN111867617A - 用于神经营养因子的诱导型表达的组合物和方法 - Google Patents

用于神经营养因子的诱导型表达的组合物和方法 Download PDF

Info

Publication number
CN111867617A
CN111867617A CN201980019683.6A CN201980019683A CN111867617A CN 111867617 A CN111867617 A CN 111867617A CN 201980019683 A CN201980019683 A CN 201980019683A CN 111867617 A CN111867617 A CN 111867617A
Authority
CN
China
Prior art keywords
cells
gdnf
expression cassette
promoter
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980019683.6A
Other languages
English (en)
Chinese (zh)
Inventor
克莱夫·斯文森
约施华·布罗尼格
阿斯兰·阿赫塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of CN111867617A publication Critical patent/CN111867617A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
CN201980019683.6A 2018-03-16 2019-03-15 用于神经营养因子的诱导型表达的组合物和方法 Pending CN111867617A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862644332P 2018-03-16 2018-03-16
US62/644,332 2018-03-16
US201862773752P 2018-11-30 2018-11-30
US62/773,752 2018-11-30
PCT/US2019/022595 WO2019178550A1 (en) 2018-03-16 2019-03-15 Methods and compositions for inducible expression of neurotrophic factors

Publications (1)

Publication Number Publication Date
CN111867617A true CN111867617A (zh) 2020-10-30

Family

ID=67907321

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980019683.6A Pending CN111867617A (zh) 2018-03-16 2019-03-15 用于神经营养因子的诱导型表达的组合物和方法

Country Status (7)

Country Link
US (1) US12258571B2 (https=)
EP (1) EP3765058A4 (https=)
JP (2) JP7535944B2 (https=)
KR (1) KR102843346B1 (https=)
CN (1) CN111867617A (https=)
AU (1) AU2019236288B2 (https=)
WO (1) WO2019178550A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466290B2 (en) 2016-01-26 2022-10-11 Cedars-Sinai Medical Center Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof
WO2025002240A1 (en) * 2023-06-29 2025-01-02 The University Of Hong Kong Method for controllable transcription in liver or liver cancer
US12258571B2 (en) 2018-03-16 2025-03-25 Cedars-Sinai Medical Center Methods and compositions for inducible expression of neurotrophic factors

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190018000A1 (en) 2016-01-12 2019-01-17 Cedars-Sinai Medical Center A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
US11913022B2 (en) 2017-01-25 2024-02-27 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
WO2018176001A2 (en) 2017-03-24 2018-09-27 Cedars-Sinai Medical Center Methods and compositions for production of fallopian tube epithelium
EP4700387A2 (en) 2018-03-23 2026-02-25 Cedars-Sinai Medical Center Methods of use of islet cells
WO2019195800A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Novel differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
WO2019195798A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Human pluripotent stem cell derived neurodegenerative disease models on a microfluidic chip
EP3787613B1 (en) 2018-04-30 2026-03-11 Cedars-Sinai Medical Center Pkc activation for use in treating early onset sporadic parkinson's disease
WO2020084168A1 (en) * 2018-10-26 2020-04-30 Icm (Institut Du Cerveau Et De La Moelle Épinière) Tetracycline compound for treating drug-induced dyskinesia
CA3158428A1 (en) * 2019-10-22 2021-04-29 Cedars-Sinai Medical Center Cortical neural progenitor cells from ipscs
US20230047254A1 (en) * 2019-12-29 2023-02-16 Gloriana Therapeutics Mammalian Cells Secreting GDNF and Their Therapeutic Use
KR20220061403A (ko) * 2020-11-06 2022-05-13 (주) 에스바이오메딕스 다능성 줄기세포 유래 신경전구세포를 포함하는 퇴행성 뇌질환 치료용 약학적 조성물
GB202312699D0 (en) * 2023-08-18 2023-10-04 Cambridge Entpr Ltd Controllable expression in mammalian cells
WO2025091023A1 (en) * 2023-10-27 2025-05-01 Northwestern University Engineered cell transfected by all-in-one vector for therapeutic agents production and delivery and applications thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228295A1 (en) * 2002-04-25 2003-12-11 Svendsen Clive N. Use of human neural stem cells secreting GDNF for treatment of parkinson's and other neurodegenerative diseases
US20120107284A1 (en) * 2006-06-30 2012-05-03 Elena Kozlova Stem cells for transplantation and methods for production thereof
CN102816793A (zh) * 2012-08-22 2012-12-12 陕西师范大学 单载体双向启动的Tet-on诱导表达系统及其构建方法和应用
WO2017131926A1 (en) * 2016-01-26 2017-08-03 Cedars-Sinai Medical Center SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2003020743A1 (en) 2001-09-05 2003-03-13 Regeneron Pharmaceuticals, Inc. Methods of expressing transgenes
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
WO2008079608A1 (en) 2006-12-21 2008-07-03 Genentech, Inc. Compositions and methods for the expression of nucleic acids
US8592211B2 (en) * 2009-03-20 2013-11-26 The Rockefeller University Enhanced PiggyBac transposon and methods for transposon mutagenesis
US20120107938A1 (en) 2009-06-29 2012-05-03 University Of Basel Methods and kits for high efficiency engineering of conditional mouse alleles
WO2013155222A2 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
WO2014127289A1 (en) * 2013-02-15 2014-08-21 International Stem Cell Corporation Use of neural cells derived from human pluripotent stem cells for the treatment of neurodegenerative diseases
JP6473077B2 (ja) * 2013-03-21 2019-02-20 国立大学法人京都大学 神経分化誘導用の多能性幹細胞
WO2014204724A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
ES2939807T3 (es) 2014-03-21 2023-04-27 Fujifilm Cellular Dynamics Inc Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización
AU2015234242B2 (en) * 2014-03-21 2020-09-24 Children's Medical Research Institute Stable gene transfer to proliferating cells
US20170274048A1 (en) 2014-03-28 2017-09-28 Buck Institute For Research On Aging Methods and compositions for modulating the imune system
EP3584312A1 (en) 2014-06-27 2019-12-25 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus e4orf1, and methods of making and using the same
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US12258571B2 (en) 2018-03-16 2025-03-25 Cedars-Sinai Medical Center Methods and compositions for inducible expression of neurotrophic factors
CA3143981A1 (en) 2019-06-17 2020-12-24 Cedars-Sinai Medical Center Systems and methods for in vivo dual recombinase-mediated cassette exchange (drmce) and disease models thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228295A1 (en) * 2002-04-25 2003-12-11 Svendsen Clive N. Use of human neural stem cells secreting GDNF for treatment of parkinson's and other neurodegenerative diseases
US20120107284A1 (en) * 2006-06-30 2012-05-03 Elena Kozlova Stem cells for transplantation and methods for production thereof
CN102816793A (zh) * 2012-08-22 2012-12-12 陕西师范大学 单载体双向启动的Tet-on诱导表达系统及其构建方法和应用
WO2017131926A1 (en) * 2016-01-26 2017-08-03 Cedars-Sinai Medical Center SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHENSHA-SHA 等: "Intrastriatal GDNF gene transfer by inducible lentivirus vectors protects dopaminergic neurons in a rat model of parkinsonism", 《EXPERIMENTAL NEUROLOGY》, vol. 261, pages 88 *
HAKAN ALDSKOGIUS 等: "Regulation of Boundary Cap Neural Crest Stem Cell Differentiation After Transplantation", 《STEMCELLS》, vol. 27, no. 7, pages 1592 - 1603 *
WANG SHUYAN 等: "Inducible regulation of GDNF expression in human neural stem cells", 《SCI CHINA LIFE SCI》, vol. 56, no. 1, pages 32 - 39, XP035163654, DOI: 10.1007/s11427-012-4424-6 *
YANG WEI-HUA 等: "Regulated Expression of Lentivirus-Mediated GDNF in Human Bone Marrow-Derived Mesenchymal Stem Cells and Its Neuroprotection on Dopaminergic Cells In Vitro", 《PLOS ONE》, vol. 8, no. 5, pages 1 - 12 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466290B2 (en) 2016-01-26 2022-10-11 Cedars-Sinai Medical Center Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof
US12258571B2 (en) 2018-03-16 2025-03-25 Cedars-Sinai Medical Center Methods and compositions for inducible expression of neurotrophic factors
WO2025002240A1 (en) * 2023-06-29 2025-01-02 The University Of Hong Kong Method for controllable transcription in liver or liver cancer

Also Published As

Publication number Publication date
US20210024955A1 (en) 2021-01-28
WO2019178550A1 (en) 2019-09-19
JP2024073654A (ja) 2024-05-29
KR20200132957A (ko) 2020-11-25
AU2019236288B2 (en) 2025-06-05
JP2021518365A (ja) 2021-08-02
US12258571B2 (en) 2025-03-25
KR102843346B1 (ko) 2025-08-06
JP7535944B2 (ja) 2024-08-19
CA3092284A1 (en) 2019-09-19
AU2019236288A1 (en) 2020-09-17
EP3765058A1 (en) 2021-01-20
EP3765058A4 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
KR102843346B1 (ko) 신경영양 인자의 유도성 발현을 위한 방법 및 조성물
JP2026053560A (ja) Ｉｐｓｃ由来の皮質神経前駆細胞
AU2019203955B2 (en) Multipartite signaling proteins and uses thereof
ES2819976T5 (es) Composiciones y usos médicos para la reprogramación de TCR con proteínas de fusión
JP2024138266A (ja) 新規Ｃａｓ１２ｂ酵素およびシステム
KR20190065251A (ko) 모듈러 AAV 전달 시스템을 통한 CRISPR-Cas 게놈 가공
Johansen et al. Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS
TW202237827A (zh) 經基因工程改造之細胞及其用途
AU2019227700B2 (en) Techniques for generating cell-based therapeutics using recombinant T cell receptor genes
KR20230019063A (ko) C9orf72 연관 질환의 치료를 위한 삼중 기능 아데노-연관 바이러스 (aav) 벡터
CN109475619A (zh) 神经元蜡样脂褐质沉积症的基因治疗
KR20230021676A (ko) 단백질 제조를 위한 핵산 구조체
CN111094569A (zh) 光控性病毒蛋白质、其基因及包含该基因的病毒载体
AU2024217163A1 (en) Transposase, transposon, transposon system, and use thereof
US20040131591A1 (en) Vector system
CN113278651B (zh) 一种可实现靶基因两种剂量表达的基因修饰模型构建方法
RU2840923C1 (ru) Конструкции нуклеиновых кислот для получения белков
CN117147870B (zh) 一种基于双细胞系统的抗骨硬化蛋白抗体活性检测方法
DK2921048T3 (en) SUS SCROFA V2G: SAFE HARBOR PLACE FOR LONG-TERM EXPRESSION AND HIGH INTEGRATION OF TRANSGENERS IN A PIG
CN114901812A (zh) 使用环状dna将抗原特异性受体基因导入至t细胞基因组的方法
Class et al. Patent application title: COMPOSITIONS AND METHODS OF USE THEREOF FOR IDENTIFYING ANTI-VIRAL AGENTS Inventors: Leor S. Weinberger (San Francisco, CA, US)
Cameron Developing Olfactory Ensheathing Cells for Ex Vivo Delivery of GDNF

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination